drugset / Trial / NCT06204614
Drug Screening Using IMD in Bladder Cancer
NaSingle-groupOpen-labelTreatment
Summary
This research study involves implanting up to 4 microdevices, each small enough to fit inside the tip of a needle, into a tumor. These devices will release microdoses (many thousands of times less than a treatment dose) of different cancer drugs into the tumor. After approximately 72 hours, the devices and small regions of surrounding tissue will be removed and studied. There will be a follow-up visit within 42 days of device removal to assess for potential safety issues or side effects.
Timeline
- Start
- 2024-06-14
- Primary completion
- 2028-07-01
- Completion
- 2028-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | — | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Enfortumab | Monoclonal antibody | — | — |
| Subject | Erdafitinib | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Ifosfamide | Small molecule | — | — |
| Subject | Methotrexate | Small molecule | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Sacituzumab | Monoclonal antibody | — | — |
| Subject | Vinblastine | Small molecule | — | — |